

Olivier Bonnot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7183707/publications.pdf>

Version: 2024-02-01

61
papers

2,388
citations

236612

25
h-index

214527

47
g-index

82
all docs

82
docs citations

82
times ranked

2952
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a suspicion index for secondary schizophrenia using the Delphi method. Australian and New Zealand Journal of Psychiatry, 2022, 56, 500-509.	1.3	2
2	Early Detection of Neurodevelopmental Disorders of Toddlers and Postnatal Depression by Mobile Health App: Observational Cross-sectional Study. JMIR MHealth and UHealth, 2022, 10, e38181.	1.8	5
3	Efficacy, Tolerability, and Acceptance of Long-Lasting Antipsychotics in Children and Adolescents: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 312-327.	0.7	4
4	Efficacy and Safety of Transcranial Electric Stimulation during the Perinatal Period: A Systematic Literature Review and Three Case Reports. Journal of Clinical Medicine, 2022, 11, 4048.	1.0	4
5	Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database. Expert Opinion on Drug Safety, 2021, 20, 225-233.	1.0	3
6	Mobile App for Parental Empowerment for Caregivers of Children With Autism Spectrum Disorders: Prospective Open Trial. JMIR Mental Health, 2021, 8, e27803.	1.7	7
7	In Search of Digital Dopamine: How Apps Can Motivate Depressed Patients, a Review and Conceptual Analysis. Brain Sciences, 2021, 11, 1454.	1.1	7
8	A randomized controlled trial of 25 sessions comparing music therapy and music listening for children with autism spectrum disorder. Psychiatry Research, 2020, 293, 113377.	1.7	19
9	Health Care Trajectories for Children With ADHD in France: Results From the QUEST Survey. Journal of Attention Disorders, 2020, 24, 52-65.	1.5	6
10	5.23 A 12-MONTH PROSPECTIVE FOLLOW-UP STUDY OF A NAÏVE PEDIATRIC POPULATION TREATED WITH ANTIPSYCHOTICS (ETAPE STUDY): INCIDENCE RATE OF ADVERSE EVENTS IN FRANCE. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, S252-S253.	0.3	0
11	Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: Results of a multicenter naturalistic study (ETAPE). European Neuropsychopharmacology, 2019, 29, 1397-1407.	0.3	14
12	Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Translational Psychiatry, 2019, 9, 274.	2.4	35
13	The MEOPaDent trial protocolâ€”an observational study of the Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) effects in paediatric dentistry. BMC Oral Health, 2019, 19, 42.	0.8	3
14	Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): Findings from the International NPC Registry. World Journal of Biological Psychiatry, 2019, 20, 310-319.	1.3	21
15	Systematic review of psychiatric signs in Niemann-Pick disease type C. World Journal of Biological Psychiatry, 2019, 20, 320-332.	1.3	38
16	De la mÃ©diation musicothÃ©rapie dans la prise en charge des troubles du spectre autistique chez lâ€™enfant: Ã©valuation, processus et modÃ©lisation. La Psychiatrie De L'enfant, 2019, Vol. 62, 147-171.	0.1	6
17	Trastornos psiquiátricos secundarios a enfermedades neurometabólicas. Revista Colombiana De Psiquiatría, 2018, 47, 244-251.	0.1	5
18	Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis. Journal of Inherited Metabolic Disease, 2018, 41, 641-646.	1.7	19

#	ARTICLE	IF	CITATIONS
19	Hormonal Risk Factors for Osteoporosis: Different Profile Among Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 719-726.	0.7	7
20	Psychiatric disorders secondary to neurometabolic disorders. <i>Revista Colombiana De Psiquiatr�a</i> (English Ed), 2018, 47, 244-251.	0.1	0
21	Self�other recognition impairments in individuals with schizophrenia: a new experimental paradigm using a double mirror. <i>NPJ Schizophrenia</i> , 2018, 4, 24.	2.0	15
22	The hidden Niemann-Pick type C patient: clinical niches for a rare inherited metabolic disease. <i>Current Medical Research and Opinion</i> , 2017, 33, 877-890.	0.9	25
23	Recommendations for the detection and diagnosis of Niemann-Pick disease type C. <i>Neurology: Clinical Practice</i> , 2017, 7, 499-511.	0.8	119
24	Influence of socioeconomic status on antipsychotic prescriptions among youth in France. <i>BMC Psychiatry</i> , 2017, 17, 82.	1.1	8
25	Oculomotor Impairments in Developmental Dyspraxia. <i>Cerebellum</i> , 2017, 16, 411-420.	1.4	5
26	Time perception of simultaneous and sequential events in early-onset schizophrenia. <i>Neurocase</i> , 2016, 22, 392-399.	0.2	6
27	Incidence of adverse events in antipsychotic-na�ve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE). <i>BMJ Open</i> , 2016, 6, e011020.	0.8	10
28	Rationale and protocol for using a smartphone application to study autism spectrum disorders: SMARTAUTISM. <i>BMJ Open</i> , 2016, 6, e012135.	0.8	5
29	Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature. <i>European Journal of Pediatrics</i> , 2016, 175, 9-18.	1.3	50
30	PHEBRE trial protocol � observational study of the prevalence of problematic use of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) and analgesics in the French sickle-cell disease population. <i>BMC Psychiatry</i> , 2015, 15, 281.	1.1	4
31	Secondary psychosis induced by metabolic disorders. <i>Frontiers in Neuroscience</i> , 2015, 9, 177.	1.4	33
32	Autism as a Disorder of Biological and Behavioral Rhythms: Toward New Therapeutic Perspectives. <i>Frontiers in Pediatrics</i> , 2015, 3, 1.	0.9	123
33	Gene�environment Interactions in Autism Spectrum Disorders: Role of Epigenetic Mechanisms. <i>Frontiers in Psychiatry</i> , 2014, 5, 53.	1.3	203
34	Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 1149-1160.	2.8	23
35	Management of Adverse Effects of Second-generation Antipsychotics in Youth. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 84-105.	0.7	12
36	Altered circadian patterns of salivary cortisol in low-functioning children and adolescents with autism. <i>Psychoneuroendocrinology</i> , 2014, 50, 227-245.	1.3	66

#	ARTICLE	IF	CITATIONS
37	Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 65.	1.2	67
38	The neuropsychiatry of inborn errors of metabolism. <i>Journal of Inherited Metabolic Disease</i> , 2013, 36, 687-702.	1.7	83
39	Children's synchrony and rhythmicity in imitation of peers: Toward a developmental model of empathy. <i>Journal of Physiology (Paris)</i> , 2013, 107, 291-297.	2.1	31
40	Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. <i>Research in Autism Spectrum Disorders</i> , 2013, 7, 167-175.	0.8	43
41	Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 309-316.	0.7	167
42	Medical and developmental risk factors of catatonia in children and adolescents: A prospective case-control study. <i>Schizophrenia Research</i> , 2012, 137, 151-158.	1.1	72
43	Utilisation des antipsychotiques chez l'enfant et l'adolescent. <i>Neuropsychiatrie De L'Enfance Et De L'Adolescence</i> , 2012, 60, 12-19.	0.1	16
44	Children and Adolescents with Severe Mental Illness Need Vitamin D Supplementation Regardless of Disease or Treatment. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 157-161.	0.7	22
45	Modulation of Brain β -Endorphin Concentration by the Specific Part of the Y Chromosome in Mice. <i>PLoS ONE</i> , 2011, 6, e16704.	1.1	13
46	Facteurs de risque psychosociaux et troubles psychiatriques des jeunes pris en charge par l'aide sociale à l'enfance et ayant recours à des soins hospitaliers. <i>Neuropsychiatrie De L'Enfance Et De L'Adolescence</i> , 2011, 59, 393-403.	0.1	17
47	Are impairments of time perception in schizophrenia a neglected phenomenon?. <i>Journal of Physiology (Paris)</i> , 2011, 105, 164-169.	2.1	59
48	Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2011, 5, 15.	1.2	52
49	Cerebrotendinous Xanthomatosis Presenting with Severe Externalized Disorder: Improvement After One Year of Treatment with Chenodeoxycholic Acid. <i>CNS Spectrums</i> , 2010, 15, 231-237.	0.7	36
50	Lorazepam, fluoxetine and packing therapy in an adolescent with pervasive developmental disorder and catatonia. <i>Journal of Physiology (Paris)</i> , 2010, 104, 309-314.	2.1	19
51	Electroconvulsive Therapy in Adolescents With the Catatonia Syndrome. <i>Journal of ECT</i> , 2010, 26, 259-265.	0.3	57
52	Pain Reactivity and Plasma β -Endorphin in Children and Adolescents with Autistic Disorder. <i>PLoS ONE</i> , 2009, 4, e5289.	1.1	127
53	Association of adolescent catatonia with increased mortality and morbidity: Evidence from a prospective follow-up study. <i>Schizophrenia Research</i> , 2009, 113, 233-240.	1.1	73
54	Are Patients With Schizophrenia Insensitive to Pain? A Reconsideration of the Question. <i>Clinical Journal of Pain</i> , 2009, 25, 244-252.	0.8	104

#	ARTICLE	IF	CITATIONS
55	Does catatonia influence the phenomenology of childhood onset schizophrenia beyond motor symptoms?. <i>Psychiatry Research</i> , 2008, 158, 356-362.	1.7	24
56	Multidisciplinary approach of organic catatonia in children and adolescents may improve treatment decision making. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1393-1398.	2.5	54
57	PRIAPISM ASSOCIATED WITH SERTRALINE. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 790-791.	0.3	8
58	Animal Models Relevant to Schizophrenia and Autism: Validity and Limitations. <i>Behavior Genetics</i> , 2007, 37, 61-78.	1.4	153
59	Clinical relevance of chronic catatonic schizophrenia in children and adolescents: Evidence from a prospective naturalistic study. <i>Schizophrenia Research</i> , 2005, 76, 301-308.	1.1	67
60	Characterising the Radio Frequency Plasma Source for Glow Discharge Optical Emission Spectroscopy. <i>ISIJ International</i> , 2002, 42, S101-S105.	0.6	4
61	Maternal Exposure to Lorazepam and Anal Atresia in Newborns: Results from a Hypothesis-Generating Study of Benzodiazepines and Malformations. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 456-458.	0.7	36